Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Benzamidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 5/20 | 0.89 |
| ▸ | F10 | P00742 | 1/20 | 0.89 |
| ▸ | F12 | P00748 | 1/20 | 0.89 |
| ▸ | F7 | P08709 | 1/20 | 0.89 |
| ▸ | F3 | P13726 | 1/20 | 0.89 |
| ▸ | PKM | P14618 | 1/20 | 0.89 |
| ▸ | BLM | P54132 | 1/20 | 0.84 |
| ▸ | PRSS1 | P07477 | 6/20 | 0.80 |
| ▸ | PRSS3 | P35030 | 5/20 | 0.80 |
| ▸ | PRSS2 | P07478 | 4/20 | 0.80 |
| ▸ | C1S | P09871 | 2/20 | 0.80 |
| ▸ | RECQL | P46063 | 1/20 | 0.80 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.80 |
| ▸ | WDR5 | P61964 | 1/20 | 0.65 |
| ▸ | PLAU | P00749 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | MASP2 | O00187 | 1/20 | 0.52 |
| ▸ | THPO | P40225 | 1/20 | 0.52 |
| ▸ | NQO2 | P16083 | 2/20 | 0.52 |
| ▸ | APEX1 | P27695 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzamidine SCHEMBL28264718 | 0.94 | F2 (0.89) | F2F10F12F7F3 | |
| Benzamidine SCHEMBL28224055 | 0.94 | F2 (0.89) | F2F10F12F7F3 | |
| Benzamidine SCHEMBL9207 | 0.94 | — | — | |
| Benzamidine SCHEMBL27781057 | 0.94 | F2 (1.00) | F2F10F12F7F3 | |
| SCHEMBL18557033 | 0.94 | F2 (1.00) | F2F10F12F7F3 | |
| Benzamidine SCHEMBL23067876 | 0.94 | F2 (1.00) | F2F10F12F7F3 | |
| Benzamidine SCHEMBL2877747 | 0.92 | F2 (0.94) | F2F10F12F7F3 | |
| Benzamidine SCHEMBL6861235 | 0.92 | BLM (1.00) | F2F10F12F7F3 | |
| Benzamidine SCHEMBL7103811 | 0.92 | F2 (0.94) | F2F10F12F7F3 | |
| Benzamidine SCHEMBL31530552 | 0.92 | F2 (0.94) | F2F10F12F7F3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | ERESINA LLC (US) | 2026-04-16 | — | — | US | disclosed |
| EP-4141980-A1 | ORGANIC LIGHT EMITTING DIODE AND A COMPOUND FOR USE THEREIN | Novaled GmbH (DE) | 2023-03-01 | — | — | EP | disclosed |
| EP-4141979-A1 | ORGANIC LIGHT EMITTING DIODE AND A COMPOUND FOR USE THEREIN | Novaled GmbH (DE) | 2023-03-01 | — | — | EP | disclosed |
| CN-113671193-A | Immunoassay method for L-FABP and assay reagent used for the same | 积水医疗株式会社 | 2021-11-19 | — | — | CN | disclosed |
| EP-3564673-B1 | L-FABP IMMUNOASSAY METHOD AND ASSAY REAGENT USED IN SAID METHOD | SEKISUI MEDICAL CO LTD (JP) | 2020-08-05 | — | — | EP | disclosed |
| CN-111004556-A | Anti-yellowing leather finishing emulsion | 王磊 | 2020-04-14 | — | — | CN | disclosed |
| CN-110563638-A | compound and organic electronic device thereof | 上海嵘彩光电材料有限公司 | 2019-12-13 | — | — | CN | disclosed |
| EP-3564673-A1 | L-FABP IMMUNOASSAY METHOD AND ASSAY REAGENT USED IN SAID METHOD | Sekisui Medical Co., Ltd. (JP) | 2019-11-06 | — | — | EP | disclosed |
| EP-3264083-B1 | L-FABP IMMUNOASSAY METHOD | SEKISUI MEDICAL CO LTD (JP) | 2019-09-25 | — | — | EP | disclosed |
| CN-109646321-A | A kind of multi-functional mildy wash and preparation method thereof | 谢鹏 | 2019-04-19 | — | — | CN | disclosed |
| EP-3264083-A1 | L-FABP IMMUNOASSAY METHOD AND ASSAY REAGENT USED IN SAID METHOD | Sekisui Medical Co., Ltd. (JP) | 2018-01-03 | — | — | EP | disclosed |
| US-20170183359-A1 | COMPOUND HAVING AGONISTIC ACTIVITY ON SOMATOSTATIN RECEPTOR, AND USE THEREOF FOR MEDICAL PURPOSES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-06-29 | — | — | US | disclosed |
| US-9630976-B2 | Compound having agonistic activity on somatostatin receptor, and use thereof for medical purposes | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-04-25 | — | — | US | disclosed |
| US-20150232478-A1 | COMPOUND HAVING AGONISTIC ACTIVITY ON SOMATOSTATIN RECEPTOR, AND USE THEREOF FOR MEDICAL PURPOSES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2015-08-20 | — | — | US | disclosed |
| EP-2871179-A1 | COMPOUND HAVING AGONISTIC ACTIVITY ON SOMATOSTATIN RECEPTOR, AND USE THEREOF FOR MEDICAL PURPOSES | ONO Pharmaceutical Co., Ltd. (JP) | 2015-05-13 | — | — | EP | disclosed |
| US-8420230-B2 | Organic light emitting diode employing luminescent efficiency improvement layer | SAMSUNG DISPLAY CO., LTD. (KR) | 2013-04-16 | — | — | US | disclosed |
| US-20120077876-A1 | Method For Improved Bioactivation Of Pharmaceuticals | DRITTE PATENTPORTFOLIO BETEILIGUNGSGESELLSCHAFT MBH & CO. KG (DE) | 2012-03-29 | — | — | US | disclosed |
| US-20100039026-A1 | Organic light emitting diode employing luminescent efficiency improvement layer | SAMSUNG DISPLAY CO., LTD. (KR) | 2010-02-18 | — | — | US | disclosed |
| EP-0230945-B1 | THROMBIN-BINDING SUBSTANCE AND PROCESS FOR PREPARING THE SAME | KOWA CO. LTD. (JP) | 1991-01-16 | — | — | EP | disclosed |
| EP-0230945-A2 | Thrombin-binding substance and process for preparing the same | KOWA CO. LTD. (JP) | 1987-08-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170183359-A1 | COMPOUND HAVING AGONISTIC ACTIVITY ON SOMATOSTATIN RECEPTOR, AND USE THEREOF FOR MEDICAL PURPOSES | SSTR2, SSTR1, SSTR3 | F2 4763/4885F10 4586/4885F12 4338/4885 |
| US-20150232478-A1 | COMPOUND HAVING AGONISTIC ACTIVITY ON SOMATOSTATIN RECEPTOR, AND USE THEREOF FOR MEDICAL PURPOSES | SSTR2, SSTR1, SSTR3 | F2 4811/4885F10 4613/4885F12 4343/4885 |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | COL2A1, COLGALT1, PLOD3 | F2 1856/4885F10 4177/4885F12 3714/4885 |
| US-20120077876-A1 | Method For Improved Bioactivation Of Pharmaceuticals | CYP2B6, CYP1A2, CYP2D6 | F2 107/4885F10 1069/4885F12 258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.